You are here
Home > Silence Therapeutics plc

SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia

SLN124 granted Orphan Drug Designation by EMA for the treatment of β-Thalassemia January 15, 2019 LONDON, Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces that its lead medicine candidate SLN124 has been granted Orphan Drug […]

Top